Skip to content
MarketScale
‹ Back to IndustriesHealthcare

New Study: Probiotic DE111® Shown to Promote a Healthy Microbiome for Immune Support in Daycare-Attending Children

KENNESAW, GA (December 2, 2020) – Deerland Probiotics and Enzymes has announced the publication of a clinical study showing that the administration of the probiotic Bacillus subtilis DE111® can modify the composition of the microbiome in preschool-aged children. The study, “Daily intake of probiotic strain Bacillus subtilis DE111 supports a healthy microbiome in children attending day-care” published in Beneficial Microbes,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
New Study: Probiotic DE111® Shown to Promote a Healthy Microbiome for Immune Support in Daycare-Attending Children

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

KENNESAW, GA (December 2, 2020) – Deerland Probiotics and Enzymes has announced the publication of a clinical study showing that the administration of the probiotic Bacillus subtilis DE111® can modify the composition of the microbiome in preschool-aged children.

The study, “Daily intake of probiotic strain Bacillus subtilis DE111 supports a healthy microbiome in children attending day-care” published in Beneficial Microbes, is an IRB-approved, randomized, double-blind, placebo-controlled four-week trial involving 91 children aged 2 to 6. Results of the study showed that daily consumption of the probiotic strain Bacillus subtilis DE111 positively modulated the gut microbiome profile without changing the overall microbiome equilibrium.

After 8 weeks of daily probiotic consumption, the researchers observed an increase in alpha-diversity at the phylum level, suggesting an expanded functional diversity of the microbiome compared to that of the children in the placebo group. Specifically, there were 9 differentially abundant taxa at the genus level found in the probiotic group, six (of the phylum bacteroidetes) grew in abundance while three (of the phylum firmicutes) were reduced. The six taxa of bacteroidetes that flourished are involved in immune regulation and reduction of inflammation. This modulation of the firmicutes/bacteroidetes ratio of the microbiome in children taking B. subtilis DE111 is a positive indication for healthy gut function.

Overall, according to the researchers, these results suggest B. subtilis DE111 supports the maintenance of a healthy gut through subtle modulations of the microbiome with significant benefits in preschool aged children.

“On the dawn of a new highly modified school year where health takes center stage, this study is highly encouraging to formulate natural, safe products for young children to promote immunity and overall well-being so they can concentrate on learning,” said John Deaton, vice president of science and technology at Deerland. “Focusing on supporting a healthy microbiome will result in more robust and effective immunity as children get older.”

Deerland Probiotics & Enzymes, based in Kennesaw, Ga., specializes in developing science-backed solutions that benefit microbiome health, using probiotic, prebiotic and enzyme technology. The company offers a line of unique, clinically validated branded products, including DE111®, PreforPro®, ProHydrolase®, Solarplast®, Glutalytic® and Bifolac® probiotic strains. Deerland collaborates with customers to develop innovative and often proprietary solutions in the dietary supplement, food and beverage, sports nutrition, and companion animal markets. In addition to branded ingredients and customized formulations, Deerland offers full turnkey products for private label through its YourBrand® portfolio. The company’s manufacturing services include bulk blends, capsules, stick packs and tablets, as well as bottling and labeling. To contact Deerland Probiotics & Enzymes, call 800.697.8179 or visit www.deerland.com.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

CMS Sets $90-$420 Per-Patient Payments for Chronic Care Tech

CMS Sets $90-$420 Per-Patient Payments for Chronic Care Tech

CMS's ACCESS payment model, fully active as of July 2026, pays companies $90 to $420 per Medicare beneficiary per year for technology-supported chronic care tied to outcomes, according to HFMA. The model also requires participants to connect through CMS-designated interoperability networks, and more tech companies than traditional providers have signed on so far.

  • 01CMS ACCESS model provides annual payments of $90 to $420 per Medicare beneficiary for chronic care supported by technology.
  • 02Payments in the ACCESS model range from $90 to $420 per beneficiary per year depending on whether specified outcome targets are met.
  • 03The initiative aims to promote the integration of technology in chronic care management.

Sep 10, 2026

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

AlphaGenome Atlas gives researchers predicted molecular effects for possible DNA changes across the human genome, helping teams prioritize variants for experimental follow-up.

  • 01The Atlas covers roughly nine billion possible single-letter DNA substitutions, according to The Verge.
  • 02Predictions can prioritize research questions but do not establish clinical findings.
  • 03The useful implementation pattern is prediction, study-specific evidence, then validation.

Sep 9, 2026

OpenAI put 10,000 AI agents on Navier–Stokes. Healthcare R&D should pay attention

OpenAI put 10,000 AI agents on Navier–Stokes. Healthcare R&D should pay attention

OpenAI says roughly 10,000 AI agents produced a proposed Navier–Stokes solution in 88 hours, followed by Lean verification. For healthcare and life sciences, the immediate signal is a research workflow built around parallel agents, code execution, provenance and formal checking—not a ready-made clinical simulator.

  • 01OpenAI's result is a proposed proof under review, not a new clinical simulation product.
  • 02The near-term B2B signal is a coordinated research stack combining agents, code and formal verification.
  • 03Healthcare buyers should evaluate provenance, reproducibility, security and cost per validated result.

Sep 9, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512